Stockholders Equity (Details) - USD ($) |
1 Months Ended | 12 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 26, 2021 |
Mar. 30, 2021 |
Oct. 28, 2019 |
Dec. 18, 2018 |
Sep. 30, 2022 |
Aug. 22, 2022 |
Jun. 26, 2022 |
Mar. 29, 2022 |
Dec. 31, 2021 |
Oct. 31, 2021 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Aug. 24, 2022 |
Jul. 28, 2021 |
Mar. 10, 2021 |
Nov. 30, 2017 |
May 31, 2017 |
|
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Common stock shares authorized | 60,000,000 | 120,000,000 | 60,000,000 | |||||||||||||||
| Common stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||
| Shares outstanding, percentage | 65.00% | |||||||||||||||||
| Earnout shares, description | A.2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. As of December 31, 2021, the condition was not achieved and the Company’s conditional undertaking to issue additional shares expired. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. | |||||||||||||||||
| Market sales agreement, description | pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Issuance Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock having an aggregate offering price of up to $50,000 through Jefferies acting as sales agent. During the year ended December 31, 2022, the Company sold 229,044 shares of Common Stock under the ATM Agreement, at an average price of $1.19 per share, raising aggregate net proceeds of approximately $273, after deducting an aggregate commission of 3%. During the year ended December 31, 2021, the Company sold 743,964 shares of Common Stock under the ATM Agreement, at an average price of $7.19 per share, raising aggregate net proceeds of approximately $5,188, after deducting an aggregate commission of 3% | |||||||||||||||||
| Issuance expenses from additional paid in capital (in Dollars) | $ 8 | $ 158 | ||||||||||||||||
| Contract liability (in Dollars) | $ 1,976,000 | |||||||||||||||||
| Preferred stock, shares authorized | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||
| Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||
| Public warrants, description | ●in whole and not in part; ●at a price of $0.01 per warrant; ●at any time during the exercise period; ●upon a minimum of 30 days prior written notice of redemption; ●if, and only if, the last sale price of the Company’s Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ●if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. | |||||||||||||||||
| Exercise price (in Dollars per share) | $ 0.37 | $ 0.66 | ||||||||||||||||
| Vesting period | 4 years | |||||||||||||||||
| Granted option shares | 20,000 | 290,000 | ||||||||||||||||
| Vesting period | 1 year | |||||||||||||||||
| Fair value at the grant date (in Dollars) | $ 1,311 | $ 5,138,000 | ||||||||||||||||
| Shares of issued warrants | 362,444 | |||||||||||||||||
| Shares issued | 362,383 | |||||||||||||||||
| Share based compensation expenses (in Dollars) | $ 923 | $ 1,102 | ||||||||||||||||
| 2019 Plan [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Grant options (in Dollars per share) | $ 1,000 | |||||||||||||||||
| Equity incentive plan, description | The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. | |||||||||||||||||
| Shares issued | 380,189 | |||||||||||||||||
| Shares increased | 1,199,291 | |||||||||||||||||
| Minimum [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Common stock shares authorized | 60,000,000 | |||||||||||||||||
| Common stock par value (in Dollars per share) | $ 0.0001 | |||||||||||||||||
| Maximum [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Common stock shares authorized | 120,000,000 | |||||||||||||||||
| Common stock par value (in Dollars per share) | $ 0.0001 | |||||||||||||||||
| Securities Purchase Agreement [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Aggregate shares | 3,750,000 | |||||||||||||||||
| Gross proceeds (in Dollars) | $ 15,000 | |||||||||||||||||
| Sold price (in Dollars per share) | $ 4 | |||||||||||||||||
| Accompanying warrant to purchase share | 0.75 | |||||||||||||||||
| Exercise price (in Dollars per share) | $ 5 | |||||||||||||||||
| Shares sold to related parties | 125,000 | |||||||||||||||||
| Warrants sold to related parties | 93,750 | |||||||||||||||||
| Securities Purchase Agreement [Member] | Common Stock [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Aggregate shares | 2,812,501 | |||||||||||||||||
| License Agreement [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Common stock per share (in Dollars per share) | $ 0.0001 | |||||||||||||||||
| Warrants to purchase common stock | 591,382 | |||||||||||||||||
| Maruho Agreement [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Total gross proceed (in Dollars) | $ 3,000,000 | |||||||||||||||||
| Common stock per share (in Dollars per share) | $ 8 | |||||||||||||||||
| Common stock shares issued | 375,000 | |||||||||||||||||
| Grant date fair value (in Dollars) | $ 1,024,000 | |||||||||||||||||
| CFF Agreement [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Agreement type, description | the Company entered into a Securities Purchase Agreement with the CF Foundation, an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company would have the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion is less than $2.57, the Company shall have the right in its sole discretion to waive the second tranche payment and in such event the CF Foundation shall not have any right to receive additional shares. However, the CF Foundation may waive the Milestone in its discretion and make the Milestone Payment nonetheless. The Company concluded that the second tranche is a freestanding financial instrument. | |||||||||||||||||
| IPO [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Consummated initial public offering | 7,000,000 | |||||||||||||||||
| Offering price (in Dollars per share) | $ 10 | |||||||||||||||||
| Total gross proceed (in Dollars) | $ 70,000 | |||||||||||||||||
| Common stock per share (in Dollars per share) | $ 11.5 | |||||||||||||||||
| Retained transaction (in Dollars) | $ 60,100 | |||||||||||||||||
| Private Placement [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Aggregate warrants shares | 2,900,000 | |||||||||||||||||
| Yeda [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Shares of issued warrants | 7,615 | |||||||||||||||||
| Founder [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Shares of issued warrants | 2,974 | |||||||||||||||||
| Options Held [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Grant options (in Dollars per share) | $ 985,530 | |||||||||||||||||
| Exercise price (in Dollars per share) | $ 7.02 | $ 1.41 | ||||||||||||||||
| Employees consideration, description | the Board of Directors approved the grant of 350,500 options to 53 employees, and one consultant under the Company’s 2019 Equity Incentive Plan, without consideration. | the Board of Directors approved the grant of 1,153,500 options to 89 employees, three senior officers, one consultant, and five directors under the Company’s 2019 Equity Incentive Plan, without consideration. | ||||||||||||||||
| Vesting period | 4 years | |||||||||||||||||
| Stock option (in Dollars) | $ 1,632 | |||||||||||||||||
| Stock option weighted-average period | 1 year 6 months 18 days | |||||||||||||||||
| Board of Directors [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Exercise price (in Dollars per share) | $ 0.66 | |||||||||||||||||
| Vesting period | 4 years | |||||||||||||||||
| BiomX Israel [Member] | ||||||||||||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||||||||||||
| Exchange for common shares | 15,069,058 | |||||||||||||||||